• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » acute myeloid leukemia

Articles Tagged with ''acute myeloid leukemia''

Microscopic image of acute myeloid leukemia (AML) cells.
Cancer

Apollo’s APL-030 shows potent antitumor activity in both in vitro and in vivo AML

April 22, 2024
In tumors with amino acid deprivation, eIF-2α kinase GCN2 is activated and triggers a signaling response to promote cell survival and proliferation. This is important in high metabolically active hematological cancers, such as acute myeloid leukemia (AML).
Read More
Digital cancer cells illustration
Cancer

Auron Therapeutics presents preclinical data on KAT2A/B degrader program

April 19, 2024
Using its artificial intelligence/machine learning platform, Aurigen, Auron Therapeutics Inc. has identified histone acetyltransferase KAT2A/B as a driver of tumor cell plasticity and designed new small-molecule degraders of KAT2A/B.
Read More
Acute myeloid leukemia
Immuno-oncology

Bivictrix’s BVX-001 awarded US orphan drug designation for AML

April 18, 2024

Bivictrix Therapeutics plc’s BVX-001 has been awarded orphan drug designation by the FDA for acute myeloid leukemia (AML).


Read More
Cancer

Global Health Drug Discovery Institute patents new METTL3 inhibitors

April 9, 2024
Global Health Drug Discovery Institute has disclosed N6-adenosine-methyltransferase catalytic subunit (METTL3) inhibitors reported to be useful for the treatment of cancer and viral infections.
Read More
Lung cancer illustration

Effector stock wilts as phase II cancer data disappoint

April 4, 2024
By Lee Landenberger
Top-line data from the phase II Kickstart study of Effector Therapeutics Inc.’s tomivosertib as a frontline treatment of non-small-cell lung cancer failed to produce data strong enough to continue development in the indication. The company has decided to halt the study, move ahead with a separate, investigator-sponsored study of tomivosertib in acute myeloid leukemia and focus on another drug in its pipeline for treating breast cancer. Effector’s stock (NASDAQ:EFTR) crumpled on the NCSLC news as shares plunged 82% on April 4 to close at $2.96 each. The closing value was the lowest the company has seen in the past 12 months.
Read More
Cancer

Inhibitors of ENL/AF9 YEATS and FLT3 disclosed in Bridge Medicines patent

April 4, 2024
Bridge Medicines LLC has divulged protein ENL (MLLT1; YEATS1) and/or FLT3 (FLK2/STK1) inhibitors potentially useful for the treatment of acute lymphocytic leukemia and acute myeloid leukemia.
Read More
Test tubes, dropper and capsules
Cancer

Eilean Therapeutics’ menin inhibitor cleared for first-in-human study in Australia

March 12, 2024
Eilean Therapeutics LLC has announced clearance by the Human Research Ethics Committee in Australia for a first-in-human phase I trial of balamenib (ZE63-0302), an oral small-molecule inhibitor of the menin-KMT2A interaction.
Read More
Photomicrograph of bone marrow aspirate showing myeloblasts of acute myeloid leukemia
Immuno-oncology

Kling Biotherapeutics’ KBA-1413 recognizes a specific form of CD43 useful for cancer

Feb. 27, 2024
Kling Biotherapeutics BV has presented preclinical data on an antibody, KBA-1413, which recognizes a specific glycoform of CD43 that is shared among acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and solid tumor cells.
Read More
Pipet, test tubes, chemical structure
Cancer

New selective BET inhibitor with improved safety profile identified

Feb. 19, 2024
Because selective BET inhibitors present better efficacy and safety than pan-BET inhibitors, current research is focused on the development of BD1- or BD2-selective inhibitors.
Read More
Microscopic image of acute myeloid leukemia (AML) cells.
Cancer

Kurome’s KME-0584 receives IND clearance for relapsed or refractory AML and high-risk MDS

Feb. 16, 2024
Kurome Therapeutics Inc. has received FDA clearance of its IND for KME-0584.
Read More
Previous 1 2 … 5 6 7 8 9 10 11 12 13 … 24 25 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • 3D heart in chest

    At CRVBC 2025: Aging is circulating in your blood

    BioWorld Science
    All kinds of substances circulate through the bloodstream. Some are beneficial, like oxygen or nutrients, and others less so, like waste products, toxins,...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe